Chronic hepatitis C in the state prison system: insights into the problems and possible solutions

  title={Chronic hepatitis C in the state prison system: insights into the problems and possible solutions},
  author={Joanne C. Imperial},
  journal={Expert Review of Gastroenterology \& Hepatology},
  pages={355 - 364}
  • J. Imperial
  • Published 1 June 2010
  • Medicine
  • Expert Review of Gastroenterology & Hepatology
The prevalence of chronic hepatitis C virus (HCV) within the correctional system is estimated to be 10–20-times greater than that which is reported in the general population. High-risk behavioral patterns probably account for the greater estimates in this population. Recent observations of more than 780 patient-inmates infected with HCV within the California Department of Corrections suggest a very high prevalence of advanced fibrosis in this population. Observational studies performed in Texas… 

Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting.

Telementoring for hepatitis C treatment in correctional facilities

Telementoring is an effective method to facilitate eligible prescriber status to medical doctors and upskill other clinicians in correctional facilities to increase capacity to treat HCV.

Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis

The findings of this study showed that the prevalence of HCV among Iranian prisoners is dramatically high and that the highest prevalence rate (53%) was among prisoners who inject drugs.

Management of Chronic Hepatitis C Virus Infection: Current Perspectives

H hepatitis C virus infection leads to hepatic inflammation, steatosis, cirrhosis, and greater risk of hepatocellular carcinoma, and clinical manifestations include acute infection, chronic infection, non-hepatic complications, and occult infection.

Improving care quality with prison telemedicine: The effects of context and multiplicity on successful implementation and use

Important considerations for prison telemedicine implementation include: differences between anticipated and realised benefits and barriers, differing wants and needs of prison and community healthcare providers, the importance of top-down and bottom-up support and consideration of logistical and clinical compatibility.

Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct‐acting antiviral therapy

Evaluated the change in treatment paradigm of people who previously injected drugs (ex‐PWID) in Hong Kong before and after the availability of direct‐acting antiviral (DAA) treatment.

Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.

This study has shown that there is no significant relationship between two SNPs Ex4-30G>C and Ivs1-4640 G>A and response to IFN therapy, and suggests that it would be better to use TaqMan SNP Genotyping to evaluate other SNPs in IFN genes.

HCV elimination: breaking down the barriers to prison based care

The mathematical modelling regarding the impact of treatment as prevention amongst PWIDs to eliminate HCV as a public health threat is presented and how the prison fits into this paradigm is presented.



Treating hepatitis C in the prison population is cost‐saving

Treatment of chronic hepatitis C with PEG IFN and ribavirin in U.S. prisons results in both improved quality of life and savings in cost for almost all segments of the inmate population.

A Framework for Management of Hepatitis C in Prisons

This paper will focus on the long-term occupants of prisons, a high proportion of incarcerated persons with HCV infection or risk factors for infection, which makes correctional facilities logical venues to implement hepatitis C prevention and medical management programs.

Hepatitis C virus infection among prisoners in the California state correctional system.

  • R. FoxS. Currie K. Page-Shafer
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
HCV infection is pervasive among the California prison population, including prisoners who are non-IDUs and women with high-risk sexual behavior, and these results should promote consideration of routine HCV antibody screening and behavioral interventions among incarcerated men and women.

Chronic Liver Disease Mortality Among Male Prison Inmates in Texas, 1989–2003

From 1989 to 2003, CLD-related death rates among male Texas prisoners were high and increased over time, particularly among Hispanics, and targeted prevention, screening, and treatment of CLD risk factors, especially HCV, should be considered as priorities of the US prison healthcare systems.

Viral Hepatitis in Incarcerated Adults: A Medical and Public Health Concern

The published medical literature regarding viral hepatitis in the US incarcerated population is reviewed and prison-based hepatitis A and hepatitis B vaccination programs, needle exchange programs, methadone maintenance programs, risk education programs, and hepatitis C virus antiviral programs, for example, are shown to be safe and effective risk reduction and management strategies.

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting.

The preliminary experience shows that an intrinsically complicated therapy can attain a relatively high success rate, even in a very unfavorable and uncomfortable context, such as a prison, where only enforced counseling, active participation of institutional health care operators, and patient's willingness to maintain an elevated level of co-operation and adherence, can overcome most structural and relational difficulties.

The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV

A strategy in which inmates with chronic HCV are evaluated and a decision regarding treatment is based upon either biochemical or histologic criteria appears to balance both the health-care rights of the inmate and the impact of treating this disease on the financial and other resources of the correctional system.

Promoting HCV Treatment Completion for Prison Inmates: New York State's Hepatitis C Continuity Program

The development of a statewide program providing continuity of hepatitis C virus (HCV) treatment to prisoners upon release to the community and protocols, a referral process, and forms are described.

Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system.

The high seroprevalence of anti-HCV-positive inmates may reflect an increased prevalence of high-risk behaviors and should be of concern to the communities to which these inmates will be released.